Chronic kidney disease is a silent, progressive condition, often diagnosed only after significant, irreversible damage has occurred. For Patañjali Chary, the founder of Oakland-based Fourth Vital, the motivation is painfully personal: his mother died of acute kidney failure 17 years ago. His company’s bet is that a combination of wearable sensors and machine learning can detect subtle physiological changes long before a patient’s lab values cross a diagnostic threshold, shifting care from reactive to proactive [fourthvital.com, Unknown].
The bet on upstream infrastructure
Fourth Vital describes its work not as a single device but as an “AI-native upstream kidney-risk infrastructure layer” [linkedin.com/in/patanjalichary, Unknown]. The core idea is a non-invasive, in-home monitoring system that tracks a combination of physiological and social biomarkers, feeding that data into an AI model designed to forecast kidney function decline. The goal is to provide clinicians and patients with an early-warning signal, potentially enabling lifestyle or pharmacological interventions that could slow disease progression. This focus on the pre-symptomatic, pre-diagnostic phase is what sets the company apart from the many digital health tools built for managing established CKD.
A team built for the clinical frontier
The company’s leadership reflects the dual technical and medical challenges of its mission. Chary brings a computer science and AI background from the University of Toronto, along with stints at Oracle and Microsoft and an MBA from Columbia and UC Berkeley [f6s.com, Unknown]. His co-founder, Dr. Hershl Berman, is a Canadian physician specializing in internal and palliative medicine, providing crucial clinical grounding [sinaihealth.ca, 2026]. The team is rounded out by experienced advisors, including board chair Rupam Shrivastava of Frontiers Capital and former product executive Kamila Agi [linkedin.com/in/rupam, Unknown]. This blend is essential for navigating the long path from research to regulated medical device.
| Role | Name | Background |
|---|---|---|
| Founder & CEO | Patañjali Chary | Computer Science/AI (Univ. of Toronto), ex-Oracle & Microsoft, MBA (Columbia/Berkeley) [f6s.com, Unknown] |
| Co-founder / Medical Lead | Dr. Hershl Berman | MD, Internal & Palliative Medicine, Sinai Health, University of Toronto [sinaihealth.ca, 2026] |
| Board Chair | Rupam Shrivastava | Founder & GP, Frontiers Capital [linkedin.com/in/rupam, Unknown] |
| Product Advisor | Kamila Agi, Ph.D. | Former executive product and design leader [linkedin.com/posts/kamilagi, Unknown] |
Early traction and a strategic accelerator
While still in the pre-commercial, research-use-only phase, Fourth Vital has begun to build the partnerships necessary for validation. The company received grant funding from MITACS Canada in partnership with London Health Sciences Centre, a major Canadian academic hospital, for clinical co-development [startupintros.com, Unknown]. A more significant signal of external validation came in 2025, when Fourth Vital was selected as one of 12 startups for the CUNY Public Health Innovation Accelerator, chosen from more than 200 applicants [LinkedIn, June 2025]. This program is designed to provide access to hospital systems, regulators, and public-health investors, a critical network for a company whose ultimate buyers may be integrated health systems or public health agencies.
Funding to date appears to be a mix of grants, angel investment, and a small pre-seed round. Public records show a total of approximately $250,000 in disclosed funding, with backing from LvlUp Ventures, EIT Health, and CUNY Firefly [vcbacked.co, Unknown]. An earlier profile indicated the company was raising a $1.25 million pre-seed SAFE to scale data collection [mindmaps.ai-ecosystem.org, Unknown], though it is unclear if that full amount was secured.
The path to proof and the risks ahead
The ambition is clear, but the road is long and fraught with the typical hurdles of clinical AI. Fourth Vital’s current position highlights several key challenges it must overcome.
- Regulatory clearance. The system is currently for research use only. Achieving FDA clearance or CE marking as a Software as a Medical Device (SaMD) will require robust clinical validation, a multi-year process with no guaranteed outcome.
- Clinical evidence. The core claim,detecting decline earlier than standard labs,must be proven in peer-reviewed studies. Early partnership with London Health Sciences Centre is a first step, but prospective clinical trials are the ultimate benchmark.
- Market focus. Public descriptions of the company oscillate between a B2C in-home device and a B2B infrastructure layer for hospitals and public health [medstartr.ai, Unknown]. Clarifying the primary customer and reimbursement pathway is a necessary strategic step.
- Competitive landscape. While no direct competitors are named in the sources, the broader field of remote patient monitoring and predictive analytics for CKD is crowded. Differentiation will hinge on the proprietary predictive power of Fourth Vital’s AI model and its clinical utility.
For the 37 million Americans living with chronic kidney disease, the standard of care today is largely reactive. Diagnosis typically follows a routine blood test showing elevated creatinine, a sign of already-diminished kidney function. Management then focuses on slowing progression through blood pressure control and medications, with advanced disease leading to dialysis or transplant. It is a costly, life-altering pathway that begins too late. Fourth Vital’s entire premise is that by moving the detection window earlier, it can change that trajectory. The next twelve months will be about turning accelerator access into concrete pilot data, and beginning the arduous but essential work of building the clinical evidence required to turn a compelling idea into a standard of care.
Sources
- [fourthvital.com, Unknown] Fourth Vital About Page | https://fourthvital.com/about-us.html
- [linkedin.com/in/patanjalichary, Unknown] Patañjali Chary LinkedIn Profile | https://www.linkedin.com/in/patanjalichary
- [f6s.com, Unknown] Fourth Vital Company Profile | https://www.f6s.com/company/fourth-vital
- [sinaihealth.ca, 2026] Dr. Hershl Berman Profile | https://sinaihealth.ca
- [linkedin.com/in/rupam, Unknown] Rupam Shrivastava LinkedIn Profile | https://www.linkedin.com/in/rupam
- [linkedin.com/posts/kamilagi, Unknown] Kamila Agi LinkedIn Post | https://www.linkedin.com/posts/kamilagi_hell-of-a-journey-congrats-and-this-activity-7336482738117496832-LEiO
- [startupintros.com, Unknown] Fourth Vital Profile | https://startupintros.com/orgs/fourth-vital
- [LinkedIn, June 2025] CUNY Accelerator Announcement | https://www.linkedin.com/posts/kamilagi_hell-of-a-journey-congrats-and-this-activity-7336482738117496832-LEiO
- [vcbacked.co, Unknown] Fourth Vital Funding | https://www.vcbacked.co/company/fourth-vital
- [mindmaps.ai-ecosystem.org, Unknown] Fourth Vital Profile | https://mindmaps.ai-ecosystem.org/map/firms/280168/
- [medstartr.ai, Unknown] Fourth Vital Directory Listing | https://www.medstartr.ai/companies/fourth-vital